Xu Shungang, Liu Xueting, Chen Xuanwen, Chen Bo, Lin Sishi, You Xiaohan, Li Duo, Zhang Ji, Chen Chaosheng
Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China.
Institute of Chronic Kidney Disease, Wenzhou Medical University, Wenzhou, Zhejiang, PR China.
Ren Fail. 2025 Dec;47(1):2512052. doi: 10.1080/0886022X.2025.2512052. Epub 2025 Jun 8.
Idiopathic membranous nephropathy (IMN) complicated with focal segmental glomerulosclerosis (FSGS) is not rare, but the impact of variant pathological manifestations of FSGS (tip variant vs non-tip variant) on the clinical and prognosis of IMN patients remains to be further studied. A total of 536 eligible IMN patients were enrolled in the study and divided into three groups based on the variant histopathological presence of FSGS: 387 patients without FSGS (IMN group), 67 patients with tip variant FSGS (tpFSGS group), and 82 patients with non-tip variant FSGS (ntpFSGS group). IMN patients with FSGS had significantly lower serum albumin (IMN vs. tpFSGS vs. ntpFSGS, 21.20 [17.15, 25.25] vs. 18.60 [16.05, 22.10] vs. 17.90 [15.40, 22.03], < 0.001) and higher 24-hour proteinuria (5.65 [3.60, 7.69] vs. 6.11 [3.97, 8.46] vs. 6.98 [4.77, 8.49], 0.003). Additionally, the ntpFSGS group exhibited more advanced histopathological manifestations (pathological stage, 0.05). Otherwise, a lower complete remission rate was observed in the ntpFSGS group. Furthermore, multivariate Cox regression analysis demonstrated significantly lower remission in tpFSGS [HR = 0.69, 0.029] and ntpFSGS [HR = 0.66, 0.014] groups. Adjusted by the immunosuppressive therapy, a worse prognosis was observed in the ntpFSGS group [KM curve, log-rank, 0.05], but no significant difference in the IMN group and the tpFSGS group [KM curve, log-rank, 0.74]. Our cohort study suggests that idiopathic membranous nephropathy patients with secondary variant FSGS indicated different clinical significance.
特发性膜性肾病(IMN)合并局灶节段性肾小球硬化(FSGS)并不罕见,但FSGS不同病理表现(顶端变异型与非顶端变异型)对IMN患者临床及预后的影响仍有待进一步研究。本研究共纳入536例符合条件的IMN患者,并根据FSGS的变异组织病理学表现分为三组:387例无FSGS的患者(IMN组)、67例顶端变异型FSGS患者(tpFSGS组)和82例非顶端变异型FSGS患者(ntpFSGS组)。合并FSGS的IMN患者血清白蛋白显著更低(IMN组 vs. tpFSGS组 vs. ntpFSGS组,21.20 [17.15, 25.25] vs. 18.60 [16.05, 22.10] vs. 17.90 [15.40, 22.03],<0.001),24小时蛋白尿更高(5.65 [3.60, 7.69] vs. 6.11 [3.97, 8.46] vs. 6.98 [4.77, 8.49],P = 0.003)。此外,ntpFSGS组表现出更严重的组织病理学表现(病理分期,P = 0.05)。否则,ntpFSGS组的完全缓解率更低。此外,多因素Cox回归分析显示tpFSGS组[HR = 0.69,P = 0.029]和ntpFSGS组[HR = 0.66,P = 0.014]缓解率显著更低。经免疫抑制治疗调整后,ntpFSGS组预后更差[KM曲线,对数秩检验,P = 0.05],但IMN组和tpFSGS组无显著差异[KM曲线,对数秩检验,P = 0.74]。我们的队列研究表明,继发变异型FSGS的特发性膜性肾病患者具有不同的临床意义。